Buscombe J
Department of Nuclear Medicine, Royal Free Hospital, London, UK.
Nucl Med Commun. 1995 Dec;16(12):990-1001. doi: 10.1097/00006231-199512000-00002.
Radiolabelled human immunoglobulins have been available for 5 years. Within that time there have been many publications on the use of these agents labelled with both technetium-99m (99Tcm) and indium-111 (111In). The results of these data appear contradictory and only now do we understand both some of the mechanisms of radiolabelled immunoglobulins and some of their limitations. While 111In-polyclonal immunoglobulin seems to have a wide range of clinical applications in infection and inflammation, the more readily available 99Tcm-labelled product is best suited to the localization of peripheral bone and joint disease. The ease of producing these agents from commercially available immunoglobulins will ensure continued interest and research into these new tracers.
放射性标记的人免疫球蛋白已问世5年。在此期间，有许多关于使用用锝-99m（99Tcm）和铟-111（111In）标记的这些制剂的出版物。这些数据的结果似乎相互矛盾，直到现在我们才了解放射性标记免疫球蛋白的一些机制及其一些局限性。虽然111In多克隆免疫球蛋白似乎在感染和炎症方面有广泛的临床应用，但更容易获得的99Tcm标记产品最适合于外周骨和关节疾病的定位。从市售免疫球蛋白生产这些制剂的简便性将确保对这些新示踪剂持续的关注和研究。
